Last updated: April 25, 2026
What does WIPO patent WO2015103490 claim and how does it shape the drug patent landscape?
What is WO2015103490 and what drug does it cover?
WO2015103490 is a PCT publication (WIPO) that relates to pharmaceutical compositions and methods involving antiretroviral drug use. The document’s scope is defined through (1) claims directed to chemical entities (or specific drug forms), compositions, and dosing regimens, and (2) method-of-treatment claims tied to therapeutic use.
Patent landscape framing for WO2015103490 rests on three layers:
- Primary claim scope: product and method claims (drug/composition + therapeutic use).
- Claim boundary mechanics: dependent claims that narrow active ingredient form, dosage, patient population, or administration route.
- Family and prosecution outcomes: national phase filings, claim amendments, and grants that determine enforceable scope.
What is the claim structure and how broad is the scope?
WO2015103490 follows standard PCT claim drafting patterns: it typically separates claim sets into independent claims (broadest coverage) and dependent claims (narrower embodiments). The enforceable scope is determined primarily by the independent claims, while dependent claims create fallback positions that can survive validity challenges.
From a landscape perspective, the key scope drivers are:
- Active ingredient definition: whether claims require a specific compound identity versus broader classes.
- Composition definition: whether claims require exact excipients, formulations, particle size, salt forms, or sustained-release matrices.
- Method definition: whether method claims are limited to specific indications, patient characteristics, dosing schedules, or treatment sequences.
- Administration and regimen: whether claims cover a single-dose concept or structured multi-dose regimens.
How do the claims typically allocate coverage (product vs method)?
In drug PCTs of this type, claim scope usually divides into:
- Product claims: drug (or salt/solvate), composition, and sometimes formulation parameters.
- Method claims: “a method for treating” a defined condition using the claimed drug/composition.
- Use claims: sometimes phrased as medical use, covering treating a specific disease state.
For WO2015103490, the landscape relevance is that product protection and method protection can be litigated separately. Even when an active ingredient is already known, patent value concentrates in:
- specific formulations (e.g., release characteristics, stability),
- specific dose/regimen,
- and specific therapeutic populations or endpoints.
What are the practical boundaries for competitors analyzing freedom-to-operate?
For competitive entry planning, WO2015103490’s scope translates into typical infringement tests:
- Exact identity match for active ingredient/salt and claimed composition components.
- Formulation equivalence: whether non-identical excipients or release mechanics still fall within the claim language.
- Regimen match: whether a competitor’s dosing schedule and indication map onto the method claims.
- Patient population and clinical intent: whether the claim requires a particular subgroup or clinical target.
If WO2015103490’s independent method claim is limited to a specific regimen or patient subset, then competitors can often design around by altering those boundaries. If independent claims cover broader “treating” language without regimen constraints, design-around is harder and enforcement risk increases.
What does the patent landscape look like around WO2015103490?
What patent families and continuing protection typically exist around this publication?
For a PCT publication like WO2015103490, enforceability and practical coverage depend on the existence and status of:
- national phase grants (EP, US, and other markets),
- continuation filings (where allowed),
- divisionals/corrections, and
- claim amendments during examination.
Landscape mapping for similar drug PCTs shows that:
- composition and method claims often survive more easily than overly broad chemical identity claims, but survival depends on prior art and claim amendments.
- registration jurisdictions differ: the same PCT text can yield different final claim sets by country.
How does WO2015103490 interact with earlier patents?
WO2015103490’s validity and strategic value depend on whether its claims were considered new over:
- earlier patents on the active ingredient,
- earlier patents on formulations,
- earlier patents on regimens and indications, and
- earlier patents on combination therapy (if the claims involve combination use).
Common landscape patterns in established drug classes:
- If earlier patents already disclose the compound and its general therapeutic use, then novelty shifts to specific dosage forms or regimen details.
- If earlier patents disclose the regimen broadly, then WO2015103490’s differentiation must be tied to a specific dosing schedule, patient subgroup, or treatment outcome.
How does it interact with later patents and generic entry risks?
Later patents in the same therapeutic area usually cluster into:
- next-generation formulations (improved release, stability, reduced dosing frequency),
- combination regimens with other agents,
- new indications, and
- new patient subgroup claims.
For generic or biosimilar planning, the key landscape question is whether WO2015103490 creates:
- a product-form barrier (formulation claims),
- a clinical-use barrier (method claims),
- or both.
If formulation claims are narrow, generics can sometimes enter productively by using alternative formulation approaches. If method claims are broad but still tied to a specific regimen, entrants often manage risk by altering dosing and indication labeling.
What is the scope of claims in terms of legal categories?
Where is the enforceable value likely concentrated?
Across PCT drug filings of this category, enforceable value typically concentrates in one or more of the following:
- Independent method-of-treatment claims with regimen and indication constraints.
- Composition claims with formulation specificity (salt/form, excipients, and release features).
- Dependent claims that preserve narrower embodiments if broader claims face novelty or inventive step objections.
For WO2015103490, the competitive takeaway is that enforceability risk should be modeled at two levels:
- broad independent coverage (initial infringement assessment),
- fallback dependent embodiments (secondary risk if independent claims narrow in prosecution).
What claim language tends to narrow or expand scope?
The most scope-sensitive elements typically include:
- whether claims define a specific salt or polymorph,
- whether claims define a specific dosage range versus open-ended dosing,
- whether claims define a specific frequency schedule (e.g., once daily, multi-day cycles),
- whether claims define a specific patient category (e.g., treatment-experienced vs naive, viral load thresholds),
- whether claims define co-administered agents or sequence of therapy.
A competitor’s design-around success usually tracks these scope-sensitive claim elements.
What are the key landscape outcomes for business decisions?
How should R&D programs use WO2015103490 in portfolio planning?
Use WO2015103490 as a scope map for:
- what claim elements are likely to be considered patentably distinct (formulation/regimen/invention points),
- what the “guardrails” are for later entrants (avoid mapping onto regimen or composition parameters), and
- where to invest for differentiated IP: if WO2015103490 is narrow on dosage forms, then R&D can focus on new formulation advantages; if it is broad on clinical method, then focus shifts to different therapeutic endpoints or regimen structures.
How should investors model enforceability and litigation exposure?
Model exposure as a function of:
- whether WO2015103490 achieved grants in key jurisdictions,
- whether claim scope survived with meaningful independent claim breadth,
- whether later patents or regulatory exclusivities provide overlapping protection.
Even if a PCT is published, enforceable value depends on national claim sets and granted status. For litigation planning, the “real” risk is the final claim language in granted jurisdictions.
Key Takeaways
- WO2015103490 is a PCT drug patent built around pharmaceutical compositions and therapeutic method coverage, with scope controlled by independent claims and constrained by dependent embodiments.
- Landscape risk and opportunity hinge on whether the claims are limited by drug form (salt/formulation), dosing regimen, and patient/indication constraints versus broad “treating” language.
- For R&D and FTO, focus infringement assessment on composition definition and regimen match, then stress-test against dependent claim fallback coverage.
- For investment decisions, treat WO2015103490 as a starting scope map, but enforceability depends on the granted national phase claim sets, not the PCT publication text alone.
FAQs
1) Does WO2015103490 protect the active ingredient itself or only formulations and use?
It protects the drug patent landscape through claims that cover pharmaceutical compositions and therapeutic methods, with independent claims and dependent claims defining the precise boundary between active ingredient coverage and formulation/use coverage.
2) What claim elements matter most for a freedom-to-operate view?
The highest-impact elements are claimed formulation parameters, salt/form identity requirements, and method-of-treatment regimen constraints (dosing frequency, dosing range, and patient/indication specification).
3) Can competitors design around WO2015103490 by changing dosing schedules?
If independent and dependent method claims specify regimen structure, changing dosing frequency, cycle structure, or patient selection can reduce mapping to the claim language. If claims are broader, design-around becomes harder.
4) How do dependent claims affect infringement risk?
Dependent claims narrow embodiments but often remain viable even if independent claims narrow or face validity challenges. Competitors should assess both independent and dependent embodiments when evaluating risk.
5) Is the PCT publication the same as enforceable patent protection in major countries?
No. Enforceable scope comes from granted claims in national phases. The PCT document defines an initial scope, but final coverage is determined by prosecution and grant outcomes per jurisdiction.
References (APA)
[1] World Intellectual Property Organization. (2015). WO2015103490 (PCT publication). WIPO.
